PropertyValue
?:abstract
  • Currently, there is no specific antiviral treatment for COVID-19. However, drugs previously developed to treat other viral infections are being tested to verify if they might also be effective against SARS-CoV-2, the virus that causes COVID-19. Twenty years ago, the F.D.A. approved Lopinavir/ritonavir (LPV/r) to treat HIV infection. LPV and ritonavir were initially purposed to inhibit 3-chymotrypsin-like protease (3CL(pro)) of SARS-CoV and MERS-CoV and preliminary promising data on its efficacy for treating people infected with those viruses were available. Therefore, due to the high genetic similarities among those viruses and SARS-CoV-2, early during COVID-19 pandemic LPV/r was also proposed as one emergency treatment. We reviewed data from the literature about LPV/r treatment and SARS-CoV-2 infection, mainly focused on the efficacy and safety of this drugs for COVID-19 treatment. We can conclude that although up to date no clear benefit has been observed with the LPV/r treatment beyond standard care, its efficacy against SARS-COV-2 infection deserves further evaluations, particularly during the very early phase of the disease.
is ?:annotates of
?:creator
?:doi
?:doi
  • 10.1016/j.bj.2020.11.005
?:journal
  • Biomed_J
?:license
  • no-cc
?:pdf_json_files
  • document_parses/pdf_json/46f401e7f7a2c9031cdbf166d6f5309c524ab6bf.json; document_parses/pdf_json/2677dc959e8782538bcf9b0a70390b85f49e66c6.json
?:pmc_json_files
  • document_parses/pmc_json/PMC7654234.xml.json
?:pmcid
?:publication_isRelatedTo_Disease
is ?:relation_isRelatedTo_publication of
?:sha_id
?:source
  • Elsevier; PMC
?:title
  • Lopinavir/ritonavir: Repurposing an old drug for HIV infection in COVID-19 treatment
?:type
?:year
  • 2020-11-10

Metadata

Anon_0  
expand all